Home > News > Protalix BioTherapeutics and Chiesi Global Rare...

Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Submission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease

Data: 28/05/2020